Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer

BACKGROUND: AZD1152, the prodrug for AZD1152-hydroxyquinazoline pyrazol anilide (HQPA), is a selective inhibitor of Aurora B kinase activity. Preclinical evaluation of AZD1152 has been reported in several human cancer models. The potentiality of this compound in combination therapy warrants further...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Azzariti, A, Bocci, G, Porcelli, L, Fioravanti, A, Sini, P, Simone, G M, Quatrale, A E, Chiarappa, P, Mangia, A, Sebastian, S, Del Bufalo, D, Del Tacca, M, Paradiso, A
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2011
Soggetti:
Translational Therapeutics
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3048212/
https://ncbi.nlm.nih.gov/pubmed/21304529
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.21
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi